Mode
Text Size
Log in / Sign up

Neuroimmune mechanisms may sustain urticaria pruritus and contribute to treatment resistanceWhy do some hives keep itching? New research points to a brain-immune connection

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider neuroimmune pathways as a contributor to chronic urticaria, but note evidence is preliminary.

A systematic review examined neuro-immune interactions in urticaria from a pruritus-centric perspective. The population of interest was patients with urticaria, but the review did not report specific study designs, sample sizes, or settings. The intervention or comparator was not specified.

The main findings suggest neuroimmune mechanisms amplify pruritic signaling, promote neurogenic inflammation, sustain mast cell activation, and contribute to chronicity and treatment resistance. Regarding therapeutic efficacy, the review states a subset of patients exhibit limited efficacy with antihistamines and omalizumab. It also reports that biologics targeting neuroimmune pathways are showing encouraging efficacy in early clinical trials. No specific effect sizes, absolute numbers, p-values, or confidence intervals were reported for these outcomes.

Safety and tolerability data were not reported. Key limitations stem from the nature of the review, which synthesizes existing evidence without providing the specific quantitative data from the underlying studies. The findings on the efficacy of novel biologics are based on early clinical trials. For clinical practice, this review highlights a potential mechanistic pathway in urticaria but does not provide actionable efficacy or safety data to guide current treatment decisions beyond established therapies.

If you've ever had hives, you know the maddening itch that comes with them. For some people, that itch doesn't go away, and standard treatments like antihistamines don't always help. A new review of the research suggests why: the problem might be a two-way street between the nervous system and the immune system. In chronic hives, nerve signals can amplify the itch, which in turn triggers more inflammation, creating a vicious cycle that keeps the condition going.

The review looked at studies involving patients with urticaria (hives). It found that in a subset of these patients, common treatments have limited effect. The researchers propose that 'neuroimmune' mechanisms—where nerves and immune cells talk to each other—are a key driver. This loop can sustain the activation of mast cells, the immune cells that release histamine and cause hives and itching.

There's a glimmer of hope in this new understanding. The review notes that early clinical trials of biologic drugs designed to target these specific neuroimmune pathways are showing 'encouraging efficacy.' However, it's crucial to remember this is a review paper that synthesizes existing evidence; it doesn't report on specific new trials, sample sizes, or how strong the effects are. The findings about the promising biologics come from early-stage research, which means more and larger studies are needed to confirm how well they work and for whom. Safety data from these trials was not reported in this review.

What this means for you:
Chronic hives may be fueled by a brain-immune loop. Early drug trials targeting it look promising.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
Urticaria is a mast cell-driven skin disease, characterized by itchiness and transient wheal development. Although histamine released from activated mast cells is central to disease pathogenesis, increasing clinical evidence indicates that a subset of patients exhibit limited efficacy to antihistamines and biologics such as omalizumab. This therapeutic limitation emphasizes the involvement of additional, non-histaminergic pathways in disease persistence. Recent studies highlight the pivotal role of neuroimmune interactions, the crosstalk between the immune and nervous systems, especially in modulating type 2 inflammation and itch. In urticaria, neuroimmune mechanisms amplify pruritic signaling, and promote neurogenic inflammation, and sustain mast cell activation, collectively contributing to chronicity and treatment resistance. Deciphering these neuroimmune loops provides new insight into urticaria pathophysiology and identifies potential molecular targets for therapy. A growing number of biologics targeting neuroimmune pathways are showing encouraging efficacy in early clinical trials. This review adopts a pruritus-centered perspective to synthesize updated advances in neuroimmune research related to urticaria and to outline future directions for mechanism-based therapy.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.